Author:
Lønning Per E.,Taylor Paul D.,Anker Gun,Iddon Julie,Wie Liv,Jørgensen Linn-Marie,Mella Olav,Howell Anthony
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83: 1142-1152, 1998
2. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
3. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, OHiggins N, Romieu G, Friederich P, Lassus M: Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9: 639-645, 1998
4. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Salle ED, Arkhipov A, Piscitelli G, Massimini G: Survival advantage of exemestane (AromasinR) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study. Proc Am Soc Clin Oncol 18: Abstr 412, p. 109a, 1999
5. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antioestrogen (ICI 1827 80) in tamoxifenresistant breast cancer. Lancet 345: 29-30, 1995
Cited by
204 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献